AG
VRTX icon

Advisor Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Advisor Group’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$3.59M Buy
16,412
+7,529
+85% +$1.52M 0.02% 537
2019
Q3 		$1.5M Sell
8,883
-3,048
-26% -$539K 0.01% 911
2019
Q2 		$2.19M Sell
11,931
-1,121
-9% -$196K 0.02% 720
2019
Q1 		$2.4M Buy
13,052
+4,405
+51% +$814K 0.02% 652
2018
Q4 		$1.43M Sell
8,647
-1,239
-13% -$215K 0.01% 764
2018
Q3 		$1.91M Buy
9,886
+4,783
+94% +$852K 0.02% 657
2018
Q2 		$866K Buy
5,103
+326
+7% +$50.5K 0.01% 947
2018
Q1 		$778K Sell
4,777
-421
-8% -$68.8K 0.01% 1020
2017
Q4 		$779K Sell
5,198
-75
-1% -$11.1K 0.01% 1050
2017
Q3 		$802K Buy
5,273
+274
+5% +$41.2K 0.01% 927
2017
Q2 		$644K Buy
4,999
+593
+13% +$71.4K 0.01% 995
2017
Q1 		$481K Buy
4,406
+63
+1% +$5.55K 0.01% 1102
2016
Q4 		$319K Buy
4,343
+69
+2% +$5.61K 0.01% 1271
2016
Q3 		$372K Buy
4,274
+245
+6% +$23.2K 0.01% 1139
2016
Q2 		$344K Buy
+4,029
New +$348K 0.01% 1123

Other funds holding VRTX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Advisor Group's VRTX Position: Q4 2019 in Review

Advisor Group increased its Vertex Pharmaceuticals (VRTX) stake by 85% in Q4 2019, buying an estimated $1.52M and bringing the position to 16,412 shares worth $3.59M. The position accounts for 0.02% of the portfolio, ranked #537.

Advisor Group first reported a position in VRTX in Q2 2016 and has held it in 15 quarters since. 814 funds tracked by Wall St. Rank hold VRTX as of Q4 2019.

  • Advisor Group held 16,412 shares of Vertex Pharmaceuticals worth $3.59M as of Q4 2019.
  • Advisor Group bought 7,529 Vertex Pharmaceuticals shares in Q4 2019, an estimated $1.52M.
  • Vertex Pharmaceuticals made up 0.02% of Advisor Group's portfolio in Q4 2019, its #537 holding.
  • Advisor Group first reported a position in Vertex Pharmaceuticals in Q2 2016 and has held it in 15 quarters since.
  • 814 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.